Through
12/30
The highest honor was bestowed for foundational discoveries that gave the world a vaccine to fight the COVID-19 pandemic.
In pre-clinical models, researchers at Penn Medicine have developed a vaccine that protects against Borrelia burgdorferi, the bacteria that causes Lyme disease.
Judith A. O’Donnell of the Perelman School of Medicine answers common questions about this year’s flu shot and the new COVID-19 vaccines.
Breaking the code of the immune system could provide a new fundamental way of understanding, treating, and preventing every type of disease. Penn Medicine is investing in key discoveries about immunity and immune system function, and building infrastructure, to make that bold idea a reality.
Penn researchers uncover a new way to target solid tumors. Using CAR T cells to remove cancer-associated fibroblasts surrounding pancreatic tumors allows T cells to infiltrate and attack the tumor cells.
The Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine is honored for pioneering the development of CAR T cell therapy, which programs patients’ own immune cells to fight their cancer.
New research from the University of Pennsylvania offers a safer path for CAR T cell immunotherapy.
Researchers at Penn Medicine have demonstrated a new potential treatment using CAR T cell therapy using a CRISPR base-editing to develop a method called “epitope editing.”
In a Q & A, June, the Richard W. Vague Professor in Immunotherapy, and Daniel Baker, a fourth-year doctoral student in Penn’s Cell and Molecular Biology department, discuss how the treatment can extend to treating diseases beyond cancer.
Treatments and vaccines are only useful in the hands of the people who need them, and Penn Medicine is working toward better access and equity for biomedical innovations.
Carl June of the Perelman School of Medicine praises New Zealand research into a new CAR T-cell cancer treatment for patients with blood cancer.
FULL STORY →
A study by Christoph Thaiss and Maayan Levy of the Perelman School of Medicine and colleagues finds that long COVID’s neurological symptoms, like brain fog, memory loss, and fatigue, may stem from serotonin reduction.
FULL STORY →
A study by Christoph Thaiss and Maayan Levy of the Perelman School of Medicine and colleagues suggests that serotonin could be a target for long COVID treatment.
FULL STORY →
A study by Christoph Thaiss and Maayan Levy of the Perelman School of Medicine and colleagues suggests that several current hypotheses for the pathophysiology of long COVID are linked by a single pathway that is connected by serotonin reduction.
FULL STORY →
A study by Christoph Thaiss and Maayan Levy of the Perelman School of Medicine and colleagues finds that long COVID is associated with lower levels of circulating serotonin, which could be relevant for its neurological, cognitive, and memory symptoms.
FULL STORY →
A study by Christoph Thaiss and Maayan Levy of the Perelman School of Medicine and colleagues shows that long COVID can deplete peripheral serotonin levels, offering a baseline for treatment with serotonin supplementation.
FULL STORY →